Search

Your search keyword '"Cheuk, Daniel"' showing total 174 results
Start Over "Cheuk, Daniel" Language english
174 results on '"Cheuk, Daniel"'

2. Survival outcomes of children with relapsed or refractory myeloid leukemia associated with Down syndrome

Author

Raghuram, Nikhil, Hasegawa, Daisuke, Nakashima, Kentaro, Rahman, Syaza, Antoniou, Evangelia, Skajaa, Torjus, Merli, Pietro, Verma, Anupam, Rabin, Karen R., Aftandilian, Catherine, Kotecha, Rishi S., Cheuk, Daniel, Jahnukainen, Kirsi, Kolenova, Alexandra, Balwierz, Walentyna, Norton, Alice, O’Brien, Maureen, Cellot, Sonia, Chopek, Ashley, Arad-Cohen, Nira, Goemans, Bianca, Rojas-Vasquez, Marta, Ariffin, Hany, Bartram, Jack, Kolb, E. Anders, Locatelli, Franco, Klusmann, Jan-Henning, Hasle, Henrik, McGuire, Bryan, Hasnain, Afia, Sung, Lillian, and Hitzler, Johann

Published
2023
Full Text
View/download PDF

5. Characterization of Pediatric Acute Myeloid Leukemia With t(7;12)(q36;p13).

Author

Östlund, Anders, Waraky, Ahmed, Staffas, Anna, Sjögren, Helene, De Moerloose, Barbara, Arad‐Cohen, Nira, Cheuk, Daniel, Navarro, Jose Maria Fernandez, Jahnukainen, Kirsi, Kaspers, Gertjan J. L., Kovalova, Zhanna, Pasauliene, Ramune, Saks, Kadri, Zeller, Bernward, Norén‐Nyström, Ulrika, Hasle, Henrik, Fogelstrand, Linda, Abrahamsson, Jonas, and Palmqvist, Lars

Published
2024
Full Text
View/download PDF

9. HLA alleles associated with asparaginase hypersensitivity in Chinese children

Author

Chua, Gilbert T., Rosa Duque, Jaime S., Cheuk, Daniel Ka Leung, Leung, Alex Wing Kwan, Wong, Wilfred Hing Sang, Liu, Anthony Pak Yin, Lee, Pamela P. W., Ha, Shau Yin, Chiang, Alan Kwok Shing, Ho, Marco Hok Kung, Chu, Wai Keung, Chan, Yuk Sing, Luk, Chun Wing, Ling, Alvin Siu Cheung, Kwan, Mike Yat Wah, Yiu, Oscar Kuen Fong, Wong, Ian Chi Kei, Lau, Yu Lung, Li, Chi Kong, Leung, Wing Hang, Chan, Godfrey Chi Fung, Ip, Patrick, and Kwok, Janette

Published
2021
Full Text
View/download PDF

10. Mitoxantrone Versus Liposomal Daunorubicin in Induction of Pediatric AML With Risk Stratification Based on Flow Cytometry Measurement of Residual Disease.

Author

Tierens, Anne, Arad-Cohen, Nira, Cheuk, Daniel, De Moerloose, Barbara, Fernandez Navarro, Jose Maria, Hasle, Henrik, Jahnukainen, Kirsi, Juul-Dam, Kristian Løvvik, Kaspers, Gertjan, Kovalova, Zanna, Lausen, Birgitte, Norén-Nyström, Ulrika, Palle, Josefine, Pasauliene, Ramune, Jan Pronk, Cornelis, Saks, Kadri, Zeller, Bernward, and Abrahamsson, Jonas

Published
2024
Full Text
View/download PDF

11. Case report: Therapy-related myeloid neoplasms in three pediatric cases with medulloblastoma.

Author

Li Shun Mak, Xiuling Li, Chan, Wilson Y. K., Leung, Alex W. K., Cheuk, Daniel K. L., Yuen, Liz Y. P., So, Jason C. C., Shau Yin Ha, and Liu, Anthony P. Y.

Subjects
CEREBELLAR tumors, MEDULLOBLASTOMA, ALKYLATING agents, TUMORS, COMBINED modality therapy, TUMORS in children
Abstract

Introduction: Medulloblastoma is the most common malignant brain tumor in children, often requiring intensive multimodal therapy, including chemotherapy with alkylating agents. However, therapy-related complications, such as therapyrelated myeloid neoplasms (t-MNs), can arise, particularly in patients with genetic predisposition syndromes. This case report presents three pediatric cases of medulloblastoma with subsequent development of t-MNs, highlighting the potential role of genetic predisposition and the importance of surveillance for hematological abnormalities in long-term survivors. Case presentation: We describe three cases of pediatric medulloblastoma who developed t-MNs after receiving chemotherapy, including alkylating agents. Two of the patients had underlying genetic predisposition syndromes (TP53 pathologic variants). The latency period between initial diagnosis of medulloblastoma and the development of secondary cancer varied among the cases, ranging from 17 to 65 months. The three cases eventually succumbed from secondary malignancy, therapy-related complications and progression of primary disease, respectively. Conclusions: This report highlights the potential association between genetic predisposition syndromes and the development of therapy-related myeloid neoplasms in pediatric medulloblastoma survivors. It underscores the importance of surveillance for hematological abnormalities among such patients. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

12. Prognostic impact of t(16;21)(p11;q22) and t(16;21)(q24;q22) in pediatric AML: a retrospective study by the I-BFM Study Group

Author

Noort, Sanne, Zimmermann, Martin, Reinhardt, Dirk, Cuccuini, Wendy, Pigazzi, Martina, Smith, Jenny, Ries, Rhonda E., Alonzo, Todd A., Hirsch, Betsy, Tomizawa, Daisuke, Locatelli, Franco, Gruber, Tanja A., Raimondi, Susana, Sonneveld, Edwin, Cheuk, Daniel K., Dworzak, Michael, Stary, Jan, Abrahamsson, Jonas, Arad-Cohen, Nira, Czogala, Malgorzata, De Moerloose, Barbara, Hasle, Henrik, Meshinchi, Soheil, van den Heuvel-Eibrink, Marry, and Zwaan, C. Michel

Published
2018
Full Text
View/download PDF

24. Characteristics and outcome of primary resistant disease in paediatric acute myeloid leukaemia.

Author

Karlsson, Lene, Cheuk, Daniel, De Moerloose, Barbara, Hasle, Henrik, Jahnukainen, Kirsi, Juul‐Dam, Kristian Løvvik, Kaspers, Gertjan, Kovalova, Zanna, Lausen, Birgitte, Nyström, Ulrika Norén, Palle, Josefine, Pronk, Cornelis Jan, Saks, Kadri, Tierens, Anne, Zeller, Bernward, and Abrahamsson, Jonas

Subjects
*ACUTE myeloid leukemia, *HEMATOPOIETIC stem cell transplantation, *SALVAGE therapy
Abstract

Summary: A significant proportion of events in paediatric acute myeloid leukaemia (AML) are caused by resistant disease (RD). We investigated clinical and biological characteristics in 66 patients with RD from 1013 children with AML registered and treated according to the NOPHO‐AML 93, NOPHO‐AML 2004, DB AML‐01 and NOPHO‐DBH AML 2012 protocols. Risk factors for RD were age10 years or older and a white‐blood‐cell count (WBC) of 100 × 109/L or more at diagnosis. The five‐year overall survival (OS) was 38% (95% confidence interval [CI]: 28%–52%). Of the 63 children that received salvage therapy with chemotherapy, 59% (N = 37) achieved complete remission (CR) with OS 57% (95% CI: 42%–75%) compared to 12% (95% CI: 4%–35%) for children that did not achieve CR. Giving more than two salvage chemotherapy courses did not increase CR rates. OS for all 43 patients receiving allogeneic haematopoietic stem cell transplantation (HSCT) was 49% (95% CI: 36%–66%). Those achieving CR and proceeding to HSCT had an OS of 56% (95% CI: 41%–77%, N = 30). This study showed that almost 40% of children with primary resistant AML can be cured with salvage therapy followed by HSCT. Children that did not achieve CR after two salvage courses with chemotherapy did not benefit from additional chemotherapy. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

33. Supportive care in pediatric acute myeloid leukemia:Expert-based recommendations of the NOPHO-DB-SHIP consortium.

Author

Arad-Cohen, Nira, Zeller, Bernward, Abrahamsson, Jonas, Fernandez Navarro, Jose Maria, Cheuk, Daniel, Palmu, Sauli, Costa, Vitor, De Moerloose, Barbara, Hasle, Henrik, Jahnukainen, Kirsi, Pronk, Cornelis Jan, Gísli Jónsson, Ólafur, Kovalova, Zhanna, Lausen, Birgitte, Munthe-Kaas, Monica, Noren-Nyström, Ulrika, Palle, Josefine, Pasauliene, Ramune, Saks, Kadri, and Kaspers, Gertjan JL

Subjects
FERTILITY preservation, TUMOR lysis syndrome, PEDIATRIC therapy, ACUTE myeloid leukemia, CARDIOTOXICITY, NEW trials
Abstract

Pediatric acute myeloid leukemia (AML) is the second most common type of pediatric leukemia. Patients with AML are at high risk for several complications such as infections, typhlitis, and acute and long-term cardiotoxicity. Despite this knowledge, there are no definite supportive care guidelines as to what the best approach is to manage or prevent these complications. The NOPHO-DB-SHIP (Nordic-Dutch-Belgian-Spain-Hong-Kong-Israel-Portugal) consortium, in preparation for a new trial in pediatric AML patients, had dedicated meetings for supportive care. In this review, the authors discuss the available data and outline recommendations for the management of children and adolescents with AML with an emphasis on hyperleukocytosis, tumor lysis syndrome, coagulation abnormalities and bleeding, infection, typhlitis, malnutrition, cardiotoxicity, and fertility preservation. Improved supportive care has significantly contributed to increased cure rates. Recommendations on supportive care are an essential part of treatment for this highly susceptible population and will further improve their outcome. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

34. Epidemiology and outcomes of pediatric transplant‐associated thrombotic microangiopathy in Hong Kong.

Author

Chan, Wilson Yau Ki, Ma, Alison Lap Tak, Chan, Eugene Yu Hin, Kan, Amanda Nim Chi, Ng, Wai Fu, Lee, Pamela Pui Wah, Cheuk, Daniel Ka Leung, Chiang, Alan Kwok Shing, Leung, Wing, and Chan, Godfrey Chi Fung

Subjects
CHILDREN'S hospitals, CHRONIC kidney failure, PAROXYSMAL hemoglobinuria
Abstract

Background: Transplant‐associated thrombotic microangiopathy (TA‐TMA) is an under‐recognized yet potentially devastating complication of hematopoietic stem cell transplantation (HSCT) which had increased awareness in recent years. This report summarizes the demographics and outcomes of pediatric TA‐TMA in Hong Kong. Methods: All patients aged below 18 years who underwent HSCT in the Hong Kong Children's Hospital and were diagnosed to have TA‐TMA during the 2‐year period from April 1, 2019 to March 31, 2021 were included. Results: A total of 73 transplants (51 allogeneic and 22 autologous) in 63 patients had been performed. Six patients (four males and two females) developed TA‐TMA at a median duration of 2.5 months post‐HSCT. The incidence rate was 9.52%. Of the six TA‐TMA patients, five underwent allogenic one underwent autologous HSCT, respectively. Three of them were histologically proven. All four patients with cyclosporine had stopped the drug once TA‐TMA was suspected. Median six doses of eculizumab were administered to five out of six patients. Three patients died (two due to fungal infection and one due to acute‐on‐chronic renal failure) within 3 months upon diagnosis of TA‐TMA. Among three survivors, two stabilized with mild stage 2 chronic kidney disease (CKD) while the other suffered from stage 5 end‐stage CKD requiring lifelong dialysis. Conclusion: In conclusion, recognition and diagnosis of TA‐TMA are challenging. Early recognition and prompt administration of complement blockage with eculizumab may be beneficial in selected cases. Further prospective research studies are recommended to improve the management and outcomes of TA‐TMA. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

36. Management of Hyperleukocytosis in Pediatric Acute Myeloid Leukemia Using Immediate Chemotherapy without Leukapheresis, in Protocol NOPHO-DBH AML-2012

Author

Zeller, Bernward, Arad-Cohen, Nira, Cheuk, Daniel, De Moerloose, Barbara, Fernandez Navarro, Jose Maria, Hasle, Henrik, Kirsi, Jahnukainen, Juul-Dam, Kristian, Kaspers, Gertjan J.L., Kovalova, Zhanna, Lausen, Birgitte, Munthe-Kaas, Monica C., Norén-Nyström, Ulrika, Palle, Josefine, Pasauliene, Ramune, Pronk, Cornelis Jan, Saks, Kadri, Tierens, Anne Maria, and Abrahamsson, Jonas

Published
2023
Full Text
View/download PDF

37. Chip-AML22 Master Protocol: An Open-Label Clinical Trial in Newly Diagnosed Pediatric De Novo Acute Myeloid Leukemia (AML) Patients Including a Linked Phase II Trial with Quizartinib in FLT3-ITD/ NPM1wt Patients - a Study By the NOPHO-DB-SHIP Consortium

Author

Kaspers, Gertjan J.L., Wijnen, Noa E., Koedijk, Joost B., Ishimaru, Sae, Benedictus, Renske, Van Opstal, Ellen C., Van Tinteren, Harm, Zwaan, C. Michel, Biserna, Noha, Downs, Pamela, Duong, Yvonne, Kamel, Yasser Mostafa, Abrahamsson, Jonas, Arad-Cohen, Nira, Bodmer, Nicole, Castillo, Luis, Cheuk, Daniel, Costa, Vitor, De Moerloose, Barbara, Fernandez Navarro, Jose Maria, Fogelstrand, Linda, Goemans, Bianca F., Hasle, Henrik, Jonsson, Olafur G., Kovalova, Zhanna, Munthe-Kaas, Monica C., Norén-Nyström, Ulrika, Palmu, Sauli, Pasauliene, Ramune, Saks, Kadri, Tierens, Anne Maria, Turkiewicz, Dominik, and Pronk, Cornelis Jan

Published
2023
Full Text
View/download PDF

38. A Randomized Comparison of Liposomal Daunorubicin/Daunorubicin Combined with Low-Dose Cytarabine and Etoposide or High-Dose Cytarabine and Fludarabine in Induction Treatment of Pediatric AML Using MRD-Based Risk Stratification in the NOPHO-DBH AML 2012 Protocol

Author

De Moerloose, Barbara, Arad-Cohen, Nira, Cheuk, Daniel, Fernandez Navarro, Jose Maria, Hasle, Henrik, Jahnukainen, Kirsi, Kaspers, Gertjan J.L., Kovalova, Zhanna, Lausen, Birgitte, Norén-Nyström, Ulrika, Palle, Josefine, Pasauliene, Ramune, Pronk, Cornelis Jan, Saks, Kadri, Tierens, Anne Maria, Zeller, Bernward, and Abrahamsson, Jonas

Published
2023
Full Text
View/download PDF

40. Successful haploidentical hematopoietic stem cell transplantation (HSCT) and durable engraftment by repeated donor lymphocyte infusions for a Chinese patient with transfusion‐dependent hemoglobin (Hb) Hammersmith and massive splenomegaly.

Author

Chan, Wilson Y. K., Chan, Nelson C. N., So, Jason C. C., Lee, Pamela P. W., Cheuk, Daniel K. L., Ha, S. Y., Chan, Godfrey C. F., and Leung, Wing

Subjects
HEMATOPOIETIC stem cell transplantation, HEMOGLOBINS, EXTRAMEDULLARY hematopoiesis, LYMPHOCYTES, CELLULAR therapy, JAUNDICE
Abstract

Background: Hemoglobin (Hb) Hammersmith is a rare form of unstable β‐chain hemoglobinopathy causing hemolytic anemia. This rare event led to a more serious transfusion‐dependent phenotype in a patient. It was successfully cured by haploidentical hematopoietic stem cell transplantation (HSCT). Methods and Results: A 9‐year‐old mainland Chinese male with a history of neonatal unconjugated hyperbilirubinemia was diagnosed to have hemoglobin (Hb) Hammersmith. He required regular blood transfusion but was unable to be transfused to desired parameters for 8 years prior to transplant due to social and geographical reasons. He subsequently developed marrow hyperplasia and progressive splenomegaly (down to umbilicus level), suggestive of extramedullary hematopoiesis. Eventually, the family came to Hong Kong and complied to a more intensive transfusion regimen and preconditioning chemotherapy 3 months prior to transplant. He underwent haploidentical HSCT using paternal TCRαβ/CD45RA‐depleted graft but suffered from graft rejection, despite splenic irradiation for massive splenomegaly. It was successfully salvaged with second HSCT with unmanipulated graft from the same donor with additional serotherapy and donor lymphocyte infusions. Conclusion: Allogenic haploidentical HSCT for hemoglobin Hammersmith is feasible but adequate immunosuppression during conditioning is crucial. Precise adoptive cell therapy can promote durable engraftment. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results